A phase II, randomized, parallel group, placebo-controlled, double-blinded, dose-finding study to evaluate efficacy, safety, tolerability, and pharmacokinetics of ABY-035 in subjects with moderate-to-severe plaque psoriasis

Trial Profile

A phase II, randomized, parallel group, placebo-controlled, double-blinded, dose-finding study to evaluate efficacy, safety, tolerability, and pharmacokinetics of ABY-035 in subjects with moderate-to-severe plaque psoriasis

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 24 Nov 2017

At a glance

  • Drugs ABY 035 (Primary)
  • Indications Psoriasis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms AFFIRM-35 Study
  • Sponsors Affibody
  • Most Recent Events

    • 06 Sep 2017 According to an Affibody media release, interim data from this trial will be presented at the 26th European Academy of Dermatology and Venereology (EADV) Congress.
    • 24 May 2017 New trial record
    • 10 May 2017 According to an Affibody media release, the first part of the study included 46 healthy volunteers that were treated with escalating doses of ABY-035.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top